key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue and Export Incentives ... As on 31-12-2024, the company has a total of 100.62 Crore shares outstanding.Cadila ...

Elara sees the ongoing weakness as an opportunity to buy into the pharma space, as it expects robust earnings growth ahead at ...

incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 67,930.56 Crore) operating in Pharmaceuticals sector. Aurobindo Pharma Ltd. key Products/Revenue Segments include ...

India plans to take away the power of state drug regulators to grant approvals to manufacture antibiotics as the country ...

Authorities are planning stricter penalties for retailers and wholesalers as part of efforts to clean up the pharma supply ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

In contrast to peptides, where several LAI medicinal products have been successfully ... He has worked with Zydus Cadila, Cadila Pharma, Panacea Biotech, and Ipca Labs in different capacities.

After hours: February 12 at 5:24:15 PM EST Loading Chart for ANIP ...

After hours: February 14 at 7:57:06 PM EST Loading Chart for RVPH ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.